

SEQUANA MEDICAL

Limited Liability Company

Registered office: Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium
VAT BE 0707.821.866 Register of Legal Entities Ghent, section Ghent

<p style="text-align: center;">INVITATION EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING to be held on Friday, 10 February 2023, at 9:00 a.m. (Belgian time)</p>

The holders of securities issued by Sequana Medical NV (the "**Company**") are invited to attend an extraordinary general shareholders' meeting of the Company before a notary public.

GENERAL INFORMATION

Date, hour and venue: The extraordinary general shareholders' meeting will be held on Friday, 10 February 2023 at 9:00 a.m. (Belgian time), at the offices of the Company at Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time. There is an attendance quorum requirement for the items 5 and 6 of the agenda of the extraordinary general shareholders' meeting. If the attendance quorum for the items 5 and 6 of the agenda of the extraordinary general shareholders' meeting were not to be reached, a second extraordinary general shareholders' meeting will be held for these items on Thursday, 2 March 2023 at 9:00 a.m. (Belgian time), unless, as the case may be, decided otherwise on behalf of the board of directors. There is no attendance quorum requirement for the other items on the agenda of the extraordinary general shareholders' meeting.

Opening of the doors: In order to facilitate the keeping of the attendance list on the day of the extraordinary general shareholders' meeting, holders of securities issued by the Company and their representatives are invited to register as from 8:15 a.m. (Belgian time).

<p>It is currently envisaged that the Company will be legally allowed to organize its extraordinary general shareholders' meeting at its offices at Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, and that the holders of securities of the Company will be allowed to physically attend the meeting as set out in this convening notice. However, the evolution of the COVID-19 pandemic is uncertain and the Belgian government may impose again measures which may have an impact on the organization of the extraordinary general shareholders' meeting, such as imposing limitations on the number of people allowed to attend gatherings. The Company will monitor the situation and potential measures in light of the COVID-19 pandemic, and may provide further updates that are relevant or have an impact on the extraordinary general shareholders' meeting on the Company's website (www.sequanamedical.com).</p>
--

AGENDA

Agenda and proposed resolutions: The agenda and proposed resolutions of the extraordinary general shareholders' meeting of the Company which, as the case may be, can be amended at the meeting on behalf of the board of directors, are as follows:

1. Appointment of independent non-executive directors

Taking into account the recommendation of the remuneration and nomination committee, the board of directors recommends that Douglas Kohrs and Alexandra Taylor Clyde be appointed as independent non-executive directors of the Company for a term as from the decision by the extraordinary general shareholders' meeting up to and including the closing of the ordinary general shareholders' meeting to be held in 2026, which will have decided upon the financial

statements for the financial year ended on 31 December 2025. For further information regarding the proposed directors, reference is made to the Company's website. Based on information made available by Douglas Kohrs and Alexandra Taylor Clyde, Douglas Kohrs and Alexandra Taylor Clyde satisfy the applicable requirements in order to be nominated as independent non-executive directors in accordance with Article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code.

Proposed resolutions:

- (a) The general shareholders' meeting resolves to appoint Douglas ("Doug") Kohrs as independent non-executive director of the Company within the meaning of Article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term as from the decision by the extraordinary general shareholders' meeting up to and including the closing of the ordinary general shareholders' meeting to be held in 2026, which will have decided upon the financial statements for the financial year ended on 31 December 2025. The remuneration of the director is as decided from time to time by the Company's general shareholders' meeting, and as set out in the Company's remuneration policy, as approved from time to time by the Company's general shareholders' meeting.
- (b) The general shareholders' meeting resolves to appoint Alexandra Taylor Clyde as independent non-executive director of the Company within the meaning of Article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term as from the decision by the extraordinary general shareholders' meeting up to and including the closing of the ordinary general shareholders' meeting to be held in 2026, which will have decided upon the financial statements for the financial year ended on 31 December 2025. The remuneration of the director is as decided from time to time by the Company's general shareholders' meeting, and as set out in the Company's remuneration policy, as approved from time to time by the Company's general shareholders' meeting.

Note: If the proposed resolutions (a) and (b) set out in above are approved by the general shareholders' meeting, the Company's board of directors will be composed of (1) Ian Crosbie, Chief Executive Officer (CEO), executive director and managing director (until 2025), (2) Pierre Chauvineau, independent director and chair of the board of directors (until 2025), (3) WIOT BV, with Wim Ottevaere as permanent representative, independent director (until 2025), (4) Rudy Dekeyser, non-executive director (until 2025), (5) Jackie Fielding, independent non-executive director (until 2026), (6) Douglas Kohrs, independent non-executive director (until 2026), and (7) Alexandra Taylor Clyde, independent non-executive director (until 2026). Erik Amble resigned as director, effective 7 September 2022.

2. Approval of amendments to the remuneration in cash of the non-executive directors

Taking into account the recommendation of the remuneration and nomination committee, the board of directors recommends to amend the remuneration of the non-executive members of the board of directors.

Proposed resolution: The general shareholders' meeting approves that the non-executive directors shall be entitled to the following annual remuneration and compensation in cash (in addition to other forms of compensation as shall be approved by the general shareholders' meeting from time to time):

- (a) The chair of the board of directors is entitled to an annual fixed fee of EUR 60,000.

- (b) The non-executive independent directors (other than the chair of the board of directors) are entitled to an annual fixed fee of EUR 34,000, plus EUR 1,750 per meeting of the board of directors attended in person.
- (c) The chair of the audit committee is entitled to an additional annual fixed fee of EUR 15,000.
- (d) The chair of the remuneration and nomination committee is entitled to an additional annual fixed fee of EUR 15,000.
- (e) The members of the audit committee and the remuneration and nomination committee (other than the chair of such committees) are entitled to an additional annual fixed fee of EUR 11,500.
- (f) The remuneration set out in paragraphs (c) to (e) shall be in addition to the remuneration set out in paragraph (a) and (b) (as applicable) and can be combined, depending on whether the eligibility criteria set out in these paragraphs have been met. The remuneration of the non-executive directors can be reduced *pro rata temporis* depending on the duration of the director's mandate, the mandate of chair or the membership of a committee during a given year. All amounts are exclusive of VAT and similar charges.
- (g) The rules set out in paragraphs (a) to (f) shall apply as from 1 July 2022.

3. Approval of the revised remuneration policy to allow for a share based remuneration for the non-executive independent directors

Submission of, discussion on, and approval of the revised remuneration policy prepared by the remuneration and nomination committee, approved by the board of directors, and amending the remuneration policy that was approved by the general shareholders' meeting of 27 May 2022, allowing for the granting of so-called "restricted share units" or "RSUs" to non-executive independent directors. The proposed features of the share units or RSUs are summarised in the proposed revised remuneration policy.

Proposed resolution: The general shareholders' meeting approves (a) the revised remuneration policy, and (b) the granting to non-executive independent directors of "restricted share units" or "RSUs" as further summarised in the revised remuneration policy, whereby the RSUs can be awarded for the first time retroactively for periods in which the director's mandate was exercised (as relevant) since the ordinary general shareholders' meeting held on 27 May 2022.

4. Approval in accordance with Article 7:151 of the Belgian Companies and Associations Code

In July 2022, the Company entered into a secured loan facility agreement (the "**Kreos Loan Agreement**") with Kreos Capital VII (UK) Limited ("**Kreos UK Limited**") in the amount of EUR 10.0 million. The Kreos Loan Agreement provides that upon the occurrence of a "change of control" (as defined in the Kreos Loan Agreement), Kreos UK Limited may declare the loans under the facility to be due and payable simultaneously with the closing of the change of control transaction, together with accrued interest thereon and any other amount then owed by the Company thereunder.

Proposed resolution: The general shareholders' meeting takes note of, approves and ratifies, insofar as required, in accordance with Article 7:151 of the Belgian Companies and Associations Code, all clauses in the Kreos Loan Agreement, which fall or could be considered to fall within the scope of Article 7:751 of the Belgian Companies and

Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders' meeting also grants a special power of attorney to each director of the Company, to the notary public Stijn Raes, to Fin-2K BV, represented by Kirsten Van Bockstaele (*Chief Financial Officer*), and to Olivier Vanoost (*Director FP&A*) (each a "**Proxy Holder**"), each Proxy Holder acting singly and with the right of substitution, to complete the formalities required by Article 7:151 of the Belgian Companies and Associations Code with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette.

5. **Submission of reports in relation to the Kreos Subscription Rights**

Submission of the following reports in relation to the Kreos Subscription Rights (as defined below):

- (a) the report of the board of directors of the Company in accordance with Articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code of 23 March 2019 (as amended) (the "**Belgian Companies and Associations Code**") in relation to the proposal to issue 875,000 new subscription rights for shares of the Company, named the "Kreos Subscription Rights", and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of Kreos Capital VII Aggregator SCSp ("**Kreos**") (and its permitted successors and assigns); and
- (b) the report of the statutory auditor of the Company in accordance with Articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code in relation to the proposal to issue 875,000 Kreos Subscription Rights, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of Kreos (and its permitted successors and assigns).

6. **Proposal to issue new Kreos Subscription Rights to Kreos Capital VII Aggregator SCSp**

Proposed resolution: The extraordinary general shareholders' meeting resolves to approve the issuance of 875,000 new subscription rights for new shares in the Company (the "**Kreos Subscription Rights**") to the benefit of Kreos (and its permitted successors and assigns), consisting of (a) 650,000 Kreos Subscription Rights (giving the right to subscribe to new shares of the Company for an aggregate maximum issue price of EUR 650,000.00) exercisable at an exercise price per underlying new share of EUR 5.31, entitling Kreos to a total of 122,410 new shares (the "**Initial Kreos Subscription Rights**"), and (b) 225,000 Kreos Subscription Rights (giving the right to subscribe to new shares of the Company for an aggregate maximum issue price of EUR 225,000.00) exercisable at an exercise price per underlying new share of EUR 5.77, entitling Kreos to a total of 38,994 new shares (the "**Subsequent Kreos Subscription Rights**"), and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of Kreos (and its permitted successors and assigns). In view thereof, the extraordinary general shareholders' meeting resolves as follows:

- (a) Terms and conditions of the subscription rights: The terms and conditions of the Kreos Subscription Rights shall be as set out in the annex to the report of the board of directors referred to in item 5(a) of the agenda (for the purpose of this resolution, the

"**Conditions**"), a copy of which shall remain attached to the minutes reflecting the present resolution. The main terms of the Kreos Subscription Rights can, for informational purposes, be summarised as follows:

- (i) *Subscription rights for ordinary shares:* The Kreos Subscription Rights give Kreos the right to subscribe for the following number of new ordinary shares of the Company:
 - (A) The 650,000 Initial Kreos Subscription Rights (giving the right to subscribe to new shares of the Company for an aggregate maximum issue price of EUR 650,000.00 at an exercise price per underlying share of EUR 5.31) entitle Kreos to 122,410 new shares of the Company;
 - (B) The 225,000 Subsequent Kreos Subscription Rights (giving the right to subscribe to new shares of the Company for an aggregate maximum issue price of EUR 225,000.00 at an exercise price per underlying share of EUR 5.77) entitle Kreos in aggregate to 38,994 new shares of the Company.

The abovementioned exercise prices of the Kreos Subscription Rights are subject to certain adjustments in case of any sub-division (or stock split) or consolidation (or reverse stock split), as set out in the Conditions.

The abovementioned Kreos Subscription Rights may be exercised in whole or in part, it being understood that Kreos Subscription Rights cannot be exercised with respect to fractions of shares.

The Conditions also provide that on one occasion only, in lieu of the payment in cash of the relevant aggregate exercise price for each of the relevant shares issuable, Kreos may in respect of all of the shares that would otherwise be issuable elect to receive a reduced number of shares, to be issued to Kreos as fully paid up, which reduced number of shares shall be determined in accordance with the formula included in Condition 6.3.3 and described in the report of the board of directors referred to in item 5(a) of the agenda (the "**Net Issuance Exercise**"). In case of Net Issuance Exercise, the relevant shares will be issuable against an issue price equal to the fractional value of the Company's shares at that time (currently rounded EUR 0.1036 per share).

- (ii) *Duration:* The Kreos Subscription Rights have an initial term of five years commencing on the date on which the Kreos Subscription Rights have been issued and expiring on the day preceding the fifth anniversary of the date of the subscription rights agreement of 19 July 2022 at midnight (*i.e.*, on 18 July 2027, at 12 a.m.), or (if earlier) the completion of (i) a public takeover bid with respect to the Company's shares and other outstanding voting securities of the Company or securities granting access to voting rights, or (ii) a sale of the entire issued share capital of the Company to a bona fide third party on arm's length terms for cash consideration (a "**Share Sale**"). To the extent that the Kreos Subscription Rights have not, or only partly, been exercised at the end of the initial five-year period and provided that no Share Sale has taken place prior to such expiry date, the Company will issue a number of new subscription rights calculated by subtracting the number of subscription rights already exercised, at conditions that shall be *mutatis mutandis* the same as the Conditions, for an additional period of two years, or (if earlier) until the completion of a Share Sale.

- (iii) Transferability: Kreos shall be entitled to transfer or assign the Kreos Subscription Rights. Notwithstanding the foregoing, Kreos (i) should notify the Company of its intent to transfer the Kreos Subscription Rights, and (ii) Kreos shall not be entitled to transfer the Kreos Subscription Rights to an entity that is a customer, competitor or supplier of the Company or a group company, or an entity that holds 20% or more of the share capital of any such customer, competitor or supplier.
- (b) Underlying shares: The Kreos Subscription Rights shall entitle the holder thereof to subscribe for new ordinary shares to be issued by the Company at the occasion of the exercise of the Kreos Subscription Rights. The new ordinary shares shall be issued as fully paid up, shall have the same rights and benefits as, and rank *pari passu* in all respects, including as to entitlements to dividends and other distributions, with, the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and other distributions in respect of which the relevant record date or due date falls on or after the date of issue of the shares.
- (c) Disapplication of the preferential subscription right to the benefit of Kreos (and its permitted successors and assigns): The general shareholders' meeting resolves, in accordance with Articles 7:191 and 7:193 of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of Kreos (and its permitted successors and assigns), and to issue the Kreos Subscription Rights to Kreos, as further explained in the report of the board of directors referred to in item 5(a) of the agenda.
- (d) Capital increase and allocation of the exercise price: Upon each exercise of the Kreos Subscription Rights and the resulting issuance of new shares, the Company's share capital will be increased. Subject to, and in accordance with, the provisions of the Conditions, upon exercise of the Kreos Subscription Rights and issue of new shares, the aggregate amount of the applicable exercise price of the relevant Kreos Subscription Rights will be allocated to the share capital of the Company. If the applicable issue price, per underlying new share issued, is greater than the fractional value of the existing shares immediately prior to the capital increase, then the applicable aggregate issue price shall be allocated in such a manner that per new share issued (i) a part of the applicable aggregate issue price equal to the fractional value of the existing shares immediately prior to the capital increase shall be booked as share capital, and (ii) the balance of the applicable aggregate issue price shall be booked as issue premium. This issue premium will be booked on a separate account as net equity on the liabilities side of the Company's balance sheet and can only be reduced in execution of a valid decision of the Company in accordance with the Belgian Companies and Associations Code. Following the issue of the new shares and the capital increase resulting therefrom, each of the shares (existing and new) shall represent the same fraction of the Company's share capital.
- (e) Powers of attorney: The board of directors is authorised to implement and execute the resolutions passed by the general shareholders' meeting in connection with the Kreos Subscription Rights, and to take all steps and carry out all formalities that shall be required by virtue of the Conditions of the Kreos Subscription Rights, the Company's articles of association and applicable law in order to issue or transfer the shares upon exercise of the Kreos Subscription Rights. Furthermore, each of the Company's directors, Fin-2K BV, represented by Kirsten Van Bockstaele (*Chief Financial Officer*), and Olivier Vanoost (*Director FP&A*), each such person acting individually and with possibility of sub-delegation and the power of subrogation, shall have the

power, upon exercise of the Kreos Subscription Rights, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise, (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company's articles of association in order to reflect the new share capital and number of outstanding shares following the exercise of the Kreos Subscription Rights, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise of the Kreos Subscription Rights to trading on the regulated market of Euronext Brussels (or such other markets on which the Company's shares will be trading at that time).

- (f) Approval in accordance with Article 7:151 of the Belgian Companies and Associations Code: The general shareholders' meeting resolves to take note, approve and ratify, insofar as required in accordance with Article 7:151 of the Belgian Companies and Associations Code, all clauses included in the Conditions, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the scope of Article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders' meeting grants a special power of attorney to each director of the Company, to the notary public Stijn Raes, to Fin-2K BV, represented by Kirsten Van Bockstaele (*Chief Financial Officer*), and to Olivier Vanoost (*Director FP&A*), each acting alone and with power of substitution, for the purpose of carrying out the formalities required by Article 7:151 of the Belgian Companies and Associations Code with respect to this resolution.

Attendance quorum: According to the Belgian Companies and Associations Code, an attendance quorum of at least 50% of the outstanding shares must be present or represented at the extraordinary general shareholders' meeting for the deliberation and voting on items 5 and 6 of the aforementioned agenda of the extraordinary general shareholders' meeting. If such attendance quorum is not reached, a second extraordinary general shareholders' meeting will be convened for these agenda items, unless, as the case may be, decided otherwise on behalf of the board of directors, and the attendance quorum requirement will not apply to such second meeting. There is no attendance quorum requirement for the deliberations and voting on the other items of the agenda of the extraordinary general shareholders' meeting.

Voting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolution referred to in item 6 of the agenda of the extraordinary general shareholders' meeting shall be passed if it is approved by a majority of 75% of the votes validly cast by the shareholders. The proposed resolutions referred to in the other items of the agenda of the extraordinary general shareholders' meeting shall be passed if they are approved by a simple majority of the votes validly cast by the shareholders. Pursuant to Article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the extraordinary general shareholders' meeting, but only with an advisory vote.

PARTICIPATION TO THE MEETING

Introduction: Holders of securities issued by the Company that wish to participate to the extraordinary general shareholders' meeting of the Company should take into account the formalities and procedures described below.

Registration date: The registration date for the extraordinary general shareholders' meeting shall be Friday, 27 January 2023 at midnight (12:00 a.m., Belgian time). Only persons owning securities issued by the Company on Friday, 27 January 2023, at midnight (12:00 a.m., Belgian time) shall be entitled to participate to, and, as the case may be, vote at the extraordinary general shareholders' meeting. Only shareholders are entitled to vote. The holders of subscription rights can participate to the extraordinary general shareholders' meeting but only with an advisory vote. Shareholders, as well as holders of subscription rights must satisfy the formalities that are described under "*Participation to the meeting*".

Participation to the meeting: In order to be able to participate to the extraordinary general shareholders' meeting, a holder of securities issued by the Company must satisfy two conditions: (i) be registered as holder of such securities on the registration date, and (ii) notify the Company, as described below:

- (i) **Registration:** Firstly, the right for a holder of securities issued by the Company to participate to and, as applicable, to vote at the extraordinary general shareholders' meeting is only granted on the basis of the registration of the securities concerned on the aforementioned registration date at midnight, via registration, in the applicable register book for the securities concerned (for registered securities) or in the accounts of a certified account holder or the relevant settlement institution for the securities concerned (for dematerialised securities).
- (ii) **Notification:** Secondly, in order to be admitted to the extraordinary general shareholders' meeting, the holders of securities issued by the Company must notify the Company that they want to participate to the meeting and must do so prior to or at the latest on Saturday, 4 February 2023. The holders of securities that wish to make such notification can make use of the registration notice form that can be obtained at the Company's registered office and on the Company's website (www.sequanamedical.com). The notice must reach the Company by mail at its registered office (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, Attention: Lies Vanneste, Director Investor Relations) or by e-mail at IR@sequanamedical.com at the latest on the sixth calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Saturday, 4 February 2023 at the latest. For the holders of dematerialised securities, the notification should include a certificate confirming the number of securities that have been registered in their name on the registration date. The certificate can be obtained by the holders of the dematerialised securities with the certified account holder, the relevant settlement institution, or the relevant financial intermediary for the securities concerned.

Voting by mail: The shareholders can vote by mail in accordance with Article 37 of the Company's Articles of Association. Votes by mail must be cast by means of the form prepared by the Company. The voting by mail form can be obtained on the Company's website (www.sequanamedical.com). The voting by mail form must be signed in handwriting or electronically. If the possibility to sign the voting by mail form electronically is used, the electronic signature must be an electronic signature within the meaning of Article 3.10 of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended, or a qualified electronic signature within the meaning of Article 3.12 of the same Regulation. Signed voting by mail forms must reach the Company by mail at its registered office (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, Attention: Lies Vanneste, Director Investor Relations) or by e-mail at IR@sequanamedical.com, at the latest on the sixth calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Saturday, 4 February 2023 at the latest. Holders of securities that wish to vote by mail must in any case comply with the formalities to participate to the meeting as explained under "*Participation to the meeting*".

Representation by proxy: The holders of securities can participate to the meeting and vote, as applicable, through a proxy holder. Proxy forms can be obtained at the Company's registered office and on the Company's website (www.sequanamedical.com). The proxy must be signed in handwriting

or electronically. The electronic signature must meet the same requirements as the electronic signature for the voting by mail form (see also "*—Voting by mail*"). Signed proxies must reach the Company by mail at its registered office (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, Attention: Lies Vanneste, Director Investor Relations) or by e-mail at IR@sequanamedical.com, at the latest on the sixth calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Saturday, 4 February 2023 at the latest. The appointment of a proxy holder must be made in accordance with the applicable rules of Belgian law, including in relation to conflicts of interest and the keeping of a register. Holders of securities that wish to be represented by proxy must, in any case comply with the formalities to participate to the meeting, as explained under "*—Participation to the meeting*".

Amendments to the agenda and additional proposed resolutions: Shareholders that alone or together with other shareholders hold at least 3% of the share capital of the Company have the right to put additional items on the agenda of the extraordinary general shareholders' meeting and to table draft resolutions in relation to items that have been or are to be included in the agenda. If the required attendance quorum for the items on the agenda of the extraordinary general shareholders' meeting is not reached and a second extraordinary general shareholders' meeting is convened to deliberate and vote on such items, this right will not apply in relation to the agenda of the second extraordinary general shareholders' meeting. Shareholders wishing to exercise this right must prove on the date of their request that they own at least 3% of the outstanding shares. The ownership must be based, for dematerialised shares, on a certificate issued by the relevant settlement institution for the shares concerned, or by a certified account holder, confirming the number of shares that have been registered in the name of the relevant shareholders, and, for registered shares, on a certificate of registration of the relevant shares in the share register book of the Company. In addition, the shareholders concerned must, in any case, comply with the formalities to participate to the meeting, as explained under "*—Participation to the meeting*", with at least 3% of the outstanding shares. A request to put additional items on the agenda and/or to table draft resolutions must be submitted in writing, and must contain, in the event of an additional agenda item, the text of the agenda item concerned and, in the event of a draft resolution, the text of the draft resolution. The request must also mention the mail or e-mail address to which the Company will send the confirmation of receipt of the request. The request must reach the Company by mail at its registered office (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, Attention: Lies Vanneste, Director Investor Relations) or by e-mail at IR@sequanamedical.com at the latest on the twenty-second calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Thursday, 19 January 2023 at the latest. In case of amendments to the agenda and additional proposed resolutions as aforementioned, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional proposed resolutions no later than on the fifteenth calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Thursday, 26 January 2023 at the latest. In addition, the Company shall make amended forms available for votes by mail and votes by proxy. Proxies and votes by mail that reach the Company prior to the publication of an amended agenda remain valid for the agenda items to which the proxies and votes by mail apply, subject, however, to applicable law and the further clarifications set out on the proxy forms and vote by mail forms.

Right to ask questions: Each holder of securities issued by the Company has the right to ask questions to the directors and the statutory auditor related to items on the agenda of a general shareholders' meeting. Questions can be asked during the meeting or can be submitted in writing prior to the meeting. Written questions must reach the Company by mail at its registered office (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium, Attention: Lies Vanneste, Director Investor Relations) or by e-mail at IR@sequanamedical.com at the latest on the sixth calendar day prior to the extraordinary general shareholders' meeting, *i.e.*, on or before Saturday, 4 February 2023 at the latest. Written and oral questions will be answered during the meeting concerned in accordance with applicable law. In addition, in order for written questions to be considered, the holders of securities issued by the Company that submitted the written questions concerned must comply with the formalities to participate to the meeting, as explained under "*—Participation to the meeting*" and/or under "*—Voting by mail*" or "*—Representation by proxy*".

Access to the meeting room: The natural persons that attend the extraordinary general shareholders' meeting in their capacity as owner of securities, holder of proxies or representative of a legal entity must be able to provide evidence of their identity in order to be granted access to the meeting room (subject to what is shared above under "*—General information*"). In addition, the representatives of legal entities must hand over the documents establishing their capacity as corporate representative or attorney-in-fact. These documents will be verified immediately before the start of the meeting.

Recommendation to use e-mail: As the deadline for the submission of voting by mail forms, proxy forms and written questions is on a Saturday during which there is usually no ordinary postal service, the Company recommends the holders of its securities to use e-mail for all communication with the Company regarding the general shareholders' meeting. The Company's e-mail address for such communication is: IR@sequanamedical.com. The Company also points at that, in addition to be physically available at the Company's registered office and distributed by mail, all forms and other documentation in relation to the general shareholders' meeting will be available on the Company's website (www.sequanamedical.com). See also "*—Available documentation*".

DATA PROTECTION

The Company is responsible for the processing of personal data it receives from, or collects about, holders of securities issued by the Company and proxy holders in the context of general shareholders' meetings. The processing of such data will be carried out for the purposes of the organisation and conduct of the relevant general shareholders' meeting, including the convening notices, registrations, participation and voting, as well as for maintaining lists or registers of security holders, and the analysis of the investor and security holder base of the Company. The data include, amongst others, identification data, the number and nature of securities of a holder of securities issued by the Company, proxies and voting instructions. This data may also be transferred to third parties for the purposes of assistance or services to the Company in connection with the foregoing. The processing of such data will be carried out, mutatis mutandis, in accordance with the Company's Privacy & Cookie Policy, available on the Company's website (<https://www.sequanamedical.com/privacy-cookie-policy>). The Company draws the attention of the holders of securities issued by the Company and proxy holders to the description of the rights they may have as data subjects, such as, among others, the right to access, the right to rectify and the right to object to processing, which are outlined in the section 'Information regarding your rights' of the aforementioned Privacy & Cookie Policy. All this does not affect the rules that apply in connection with the registration and participation to the general shareholders' meeting. To exercise rights as a data subject and for all other information regarding the processing of personal data by or on behalf of the Company, the Company can be contacted by e-mail at dataprotection@sequanamedical.com.

AVAILABLE DOCUMENTATION

The following documentation is available on the Company's website (<https://www.sequanamedical.com/investors/shareholder-information>): the notice convening the extraordinary general shareholders' meeting, the agenda and proposed resolutions, or, if no resolutions are proposed, a commentary by the board of directors, updates of the agenda and proposed resolutions (in case of amendments to the agenda and proposed resolutions), the documents to be submitted to the extraordinary general shareholders' meeting as referred to in the agenda of the meeting, the attendance form, the vote by mail form, and the proxy form. Prior to the extraordinary general shareholders' meeting, holders of securities of the Company can also obtain at the registered office of the Company (Kortrijksesteenweg 1112 (box 102), 9051 Ghent, Belgium), free of cost, a copy of this documentation. The aforementioned website also mentions the total number of outstanding shares and voting rights of the Company.

On behalf of the board of directors,

THIS DOCUMENT IS NOT AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SHARES, SUBSCRIPTION RIGHTS OR OTHER SECURITIES OF SEQUANA MEDICAL NV. THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (DIRECTLY OR INDIRECTLY) IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL.